Malignant mesothelioma treated with immune checkpoint inhibitors with or without cancer vaccine (the NIPU-study) Updates
09.01.2023
The trial has completed accrual and randomised 118 patients.
The trial has completed accrual and randomised 118 patients.
15.11.2022
A total of 109 patients are included in the trial. Only 9 patients remain to be included before completion of 118 patients.
30.11.2021
Rigshospitalet, Copenhagen, Denmark, has been initiated as study site
01.09.2021
Val d’Hebron, Barcelona, Spain, has been initiated as study site
17.12.2020
Karolinska Institutet, Stockholm, Sweden, has been initiated as study site
17.11.2020
Aalborg University Hospital, Ålborg, Denmark, has been initiated as study site
29.10.2020
University of Western Australia, Perth, is now initiated as a sight and will shortly start inclusion of patients
24.09.2020
Oslo University Hospital started inclusion in May 2020. Other sites are expected to start inclusion in November 2020.